{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:46:28Z","timestamp":1777423588291,"version":"3.51.4"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":950,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"DSTL Porton Down","award":["Personal fellowship"],"award-info":[{"award-number":["Personal fellowship"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,17]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Globally, there are a number of emerging pathogens. For most, there are no licensed vaccines available for human use, although there is ongoing research and development. However, given the extensive and increasing list of emerging pathogens and the investment required to bring vaccines into clinical use, the task is huge. Overlaid on this task is the risk of anti-microbial resistance (AMR) acquisition by micro-organisms which can endow a relatively harmless organism with pathogenic potential. Furthermore, climate change also introduces a challenge by causing some of the insect vectors and environmental conditions prevalent in tropical regions to begin to spread out from these traditional areas, thus increasing the risk of migration of zoonotic disease.<\/jats:p>\n               <jats:p>Vaccination provides a defence against these emerging pathogens. However, vaccines for pathogens which cause severe, but occasional, disease outbreaks in endemic pockets have suffered from a lack of commercial incentive for development to a clinical standard, encompassing Phase III clinical trials for efficacy. An alternative is to develop such vaccines to request US Emergency Use Authorization (EUA), or equivalent status in the United States, Canada and the European Union, making use of a considerable number of regulatory mechanisms that are available prior to licensing. This review covers the status of vaccine development for some of the emerging pathogens, the hurdles that need to be overcome to achieve EUA or an equivalent regional or national status and how these considerations may impact vaccine development for the future, such that a more comprehensive stockpile of promising vaccines can be achieved.<\/jats:p>","DOI":"10.1111\/cei.13284","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T01:47:25Z","timestamp":1555033645000},"page":"170-183","source":"Crossref","is-referenced-by-count":16,"title":["Vaccines for emerging pathogens: prospects for licensure"],"prefix":"10.1093","volume":"198","author":[{"given":"E D","family":"Williamson","sequence":"first","affiliation":[{"name":"CBR Division, Defence Science and Technology Laboratory, Salisbury, Wiltshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G E","family":"Westlake","sequence":"additional","affiliation":[{"name":"CBR Division, Defence Science and Technology Laboratory, Salisbury, Wiltshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"2022021406251049000_cei13284-bib-0001","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1128\/JVI.03273-12","article-title":"A case for the ancient origin of coronaviruses","volume":"87","author":"Wertheim","year":"2013","journal-title":"J Virol"},{"key":"2022021406251049000_cei13284-bib-0002","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/v9120364","article-title":"Identification of Alpha and beta coronaviruses in wildlife species in France: bats, rodents, rabbits and hedgehogs","volume":"9","author":"Monchatre-Leroy","year":"2017","journal-title":"Viruses"},{"key":"2022021406251049000_cei13284-bib-0003","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/bmj.1.5448.1467","article-title":"Cultivation of novel type of common-cold virus in organ cultures","volume":"1","author":"Tyrrell","year":"1965","journal-title":"BMJ"},{"key":"2022021406251049000_cei13284-bib-0004","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3181\/00379727-121-30734","article-title":"A new virus isolated from the human respiratory tract","volume":"121","author":"Hamre","year":"1966","journal-title":"Proc Soc Exp Biol Med"},{"key":"2022021406251049000_cei13284-bib-0005","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N Engl J Med"},{"key":"2022021406251049000_cei13284-bib-0006","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N Engl J Med"},{"key":"2022021406251049000_cei13284-bib-0007","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1098\/rstb.2004.1489","article-title":"The aetiology of SARS: Koch\u2019s postulates fulfilled","volume":"359","author":"Drosten","year":"2004","journal-title":"Phil Trans R Soc Lond B Biol Sci"},{"key":"2022021406251049000_cei13284-bib-0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/2049-632X.12166","article-title":"The emergence of the Middle East Respiratory Syndrome coronavirus","volume":"71","author":"Price","year":"2014","journal-title":"Pathog Dis"},{"key":"2022021406251049000_cei13284-bib-0009","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1128\/JVI.06540-11","article-title":"Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus","volume":"86","author":"Woo","year":"2012","journal-title":"J Virol"},{"key":"2022021406251049000_cei13284-bib-0010","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1073\/pnas.0506735102","article-title":"Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats","volume":"102","author":"Lau","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022021406251049000_cei13284-bib-0011","first-page":"325","article-title":"Bats, civets and the emergence of SARS","volume":"315","author":"Wang","year":"2007","journal-title":"Curr Top Microbiol Immunol"},{"key":"2022021406251049000_cei13284-bib-0012","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3201\/eid1212.060401","article-title":"Review of bats and SARS","volume":"12","author":"Wang","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2022021406251049000_cei13284-bib-0013","volume-title":"Blueprint programme","author":"WHO"},{"key":"2022021406251049000_cei13284-bib-0014","author":"NAIAD\/NIH priority list of pathogens"},{"key":"2022021406251049000_cei13284-bib-0015","author":"CDC priority list of pathogens"},{"key":"2022021406251049000_cei13284-bib-0016","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.epidem.2018.05.001","article-title":"The 2017 plague outbreak in Madagascar: data descriptions and epidemic modelling","volume":"25","author":"Nguyen","year":"2018","journal-title":"Epidemics"},{"key":"2022021406251049000_cei13284-bib-0017","author":"WHO priority list of bacteria"},{"key":"2022021406251049000_cei13284-bib-0018","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.vaccine.2018.01.069","article-title":"RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype","volume":"36","author":"Nielsen","year":"2018","journal-title":"Vaccine"},{"key":"2022021406251049000_cei13284-bib-0019","author":"Malaria Vaccine Implementation Programme (MVIP) - Programme Advisory Group"},{"key":"2022021406251049000_cei13284-bib-0020","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001261.pub4","article-title":"Vaccines for preventing typhoid fever","author":"Milligan","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2022021406251049000_cei13284-bib-0021","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/21645515.2017.1392422","article-title":"Global economic evaluation of oral cholera vaccine: a systematic review","volume":"14","author":"Teoh","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2022021406251049000_cei13284-bib-0022","doi-asserted-by":"crossref","DOI":"10.21037\/arh.2017.08.08","article-title":"Diagnosis and treatment of tuberculosis: latest developments and future priorities","author":"Kumar","year":"2017","journal-title":"Ann Res Hosp"},{"key":"2022021406251049000_cei13284-bib-0023","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis","volume":"271","author":"Colditz","year":"1994","journal-title":"JAMA"},{"key":"2022021406251049000_cei13284-bib-0024","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","article-title":"Variation in protection by BCG: implications of and for heterologous immunity","volume":"346","author":"Fine","year":"1995","journal-title":"Lancet"},{"key":"2022021406251049000_cei13284-bib-0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/trstmh\/trw006","article-title":"Drug-resistant TB: deadly, costly and in need of a vaccine","volume":"110","author":"Manjelievskaia","year":"2016","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2022021406251049000_cei13284-bib-0026","volume-title":"Genomic analysis offers insight into 2018 Nigeria Lassa fever outbreak"},{"key":"2022021406251049000_cei13284-bib-0027","volume-title":"Dengue and severe dengue"},{"key":"2022021406251049000_cei13284-bib-0028","article-title":"Ecological niche modeling for filoviruses: a risk map for Ebola and Marburg virus disease outbreaks in Uganda","author":"Nyakarahuka","year":"2017","journal-title":"PLOS Curr Outbreaks"},{"key":"2022021406251049000_cei13284-bib-0029","article-title":"Yellow fever in Africa and the Americas: a historical and epidemiological perspective","volume":"24","author":"Chippaux","year":"2018","journal-title":"J Venom Ani Toxins Incl Trop Dis"},{"key":"2022021406251049000_cei13284-bib-0030","doi-asserted-by":"crossref","first-page":"e000530","DOI":"10.1136\/bmjgh-2017-000530","article-title":"Zika, chikungunya and dengue: the causes and threats of new and re-emerging arboviral diseases","volume":"3","author":"Paix\u00e3o","year":"2017","journal-title":"BMJ Glob Health"},{"key":"2022021406251049000_cei13284-bib-0031","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bjid.2015.10.004","article-title":"Chikungunya: bending over the Americas and the rest of the world","volume":"20","author":"Madariaga","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"2022021406251049000_cei13284-bib-0032","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/ijerph15010096","article-title":"The Zika virus epidemic in Brazil: from discovery to future implications","volume":"15","author":"Lowe","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"2022021406251049000_cei13284-bib-0033","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2471\/BLT.16.171082","article-title":"Zika: the origin and spread of a mosquito-borne virus","volume":"94","author":"Kindhauser","year":"2016","journal-title":"Bull World Health Org"},{"key":"2022021406251049000_cei13284-bib-0034","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/CMR.00072-15","article-title":"Zika virus","volume":"29","author":"Musso","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2022021406251049000_cei13284-bib-0035","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3201\/eid2311.171140","article-title":"Outbreak of Zika virus infections, Dominica, 2016","volume":"23","author":"Ryan","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2022021406251049000_cei13284-bib-0036","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The pathogenesis of Rift Valley fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses"},{"key":"2022021406251049000_cei13284-bib-0037","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3201\/eid2402.160122","article-title":"Ecologic features of plague outbreak areas, Democratic Republic of the Congo, 2004\u20132014","volume":"24","author":"Abedi","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2022021406251049000_cei13284-bib-0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005425","article-title":"Mechanism study on a plague outbreak driven by the construction of a large reservoir in southwest china (surveillance from 2000\u20132015)","author":"Wang","year":"2017","journal-title":"PLOS Negl Trop Dis"},{"key":"2022021406251049000_cei13284-bib-0039","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1099\/jmm.0.037960-0","article-title":"The natural history and incidence of Yersinia pestis and prospects for vaccination","volume":"61","author":"Williamson","year":"2012","journal-title":"J Med Microbiol"},{"key":"2022021406251049000_cei13284-bib-0040","doi-asserted-by":"crossref","first-page":"14043","DOI":"10.1073\/pnas.96.24.14043","article-title":"Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis","volume":"96","author":"Achtman","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022021406251049000_cei13284-bib-0041","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1086\/604718","article-title":"Plague into the 21st century","volume":"49","author":"Butler","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022021406251049000_cei13284-bib-0042","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1749-4877.2011.00277.x","article-title":"Yersinia pestis: examining wildlife plague surveillance in China and USA","volume":"7","author":"Bevins","year":"2012","journal-title":"Integ Zool"},{"key":"2022021406251049000_cei13284-bib-0043","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4269\/ajtmh.1994.51.109","article-title":"Cat-transmitted fatal pneumonic plague in a person who travelled from Colorado to Arizona","volume":"51","author":"Doll","year":"1994","journal-title":"Am J Trop Med Hyg"},{"key":"2022021406251049000_cei13284-bib-0044","volume-title":"Madagascar: Plague Outbreak - Sep 2017"},{"key":"2022021406251049000_cei13284-bib-0045","volume-title":"CDC plague treatment"},{"key":"2022021406251049000_cei13284-bib-0046","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3201\/eid0701.010106","article-title":"Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis","volume":"7","author":"Guiyoule","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"2022021406251049000_cei13284-bib-0047","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1128\/AAC.00306-06","article-title":"Resistance of Yersinia pestis to antimicrobial agents","volume":"50","author":"Galimand","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022021406251049000_cei13284-bib-0048","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/tropicalmed3020038","article-title":"Melioidosis in Thailand: present and future","volume":"3","author":"Hinjoy","year":"2018","journal-title":"Trop Med Infect Dis"},{"key":"2022021406251049000_cei13284-bib-0049","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1017\/S0950268818002492","article-title":"Tularemia transmission to humans: a multifaceted surveillance approach","volume":"146","author":"Akhvlediani","year":"2018","journal-title":"Epidemiol Infect"},{"key":"2022021406251049000_cei13284-bib-0050","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12879-018-3135-4","article-title":"Airborne geographical dispersal of Q fever from livestock holdings to human communities: a systematic review and critical appraisal of evidence","volume":"18","author":"Clark","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2022021406251049000_cei13284-bib-0051","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/vaccines5030029","article-title":"Current status of rift valley fever vaccine development","volume":"5","author":"Faburay","year":"2017","journal-title":"Vaccines (Basel)"},{"key":"2022021406251049000_cei13284-bib-0052","first-page":"261","article-title":"The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from WHO\/FAO meeting","volume":"61","author":"World Health Organization (WHO)","year":"1983","journal-title":"Bull World Health Org"},{"key":"2022021406251049000_cei13284-bib-0053","doi-asserted-by":"crossref","first-page":"e0200213","DOI":"10.1371\/journal.pone.0200213","article-title":"Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles","volume":"13","author":"Whelan","year":"2018","journal-title":"PLoS ONE"},{"key":"2022021406251049000_cei13284-bib-0054","doi-asserted-by":"crossref","first-page":"e0205882","DOI":"10.1371\/journal.pone.0205882","article-title":"Standardized guinea pig model for Q fever vaccine reactogenicity","volume":"13","author":"Baeten","year":"2018","journal-title":"PLOS ONE"},{"key":"2022021406251049000_cei13284-bib-0055","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3389\/fimmu.2016.00602","article-title":"Plague Vaccine Development: Current Research and Future Trends","volume":"7","author":"Verma","year":"2016","journal-title":"Front Immunol"},{"key":"2022021406251049000_cei13284-bib-0056","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3855\/jidc.2030","article-title":"Developing live vaccines against plague","volume":"5","author":"Sun","year":"2011","journal-title":"J Infect Dev Ctries"},{"key":"2022021406251049000_cei13284-bib-0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2014.82","article-title":"Russian vaccines against especially dangerous bacterial pathogens","volume":"3","author":"Feodorova","year":"2014","journal-title":"Emerg Microbes Infect"},{"key":"2022021406251049000_cei13284-bib-0058","volume-title":"CEPI new vaccines for a safer world"},{"key":"2022021406251049000_cei13284-bib-0059","volume-title":"About Gavi, the Vaccine Alliance"},{"key":"2022021406251049000_cei13284-bib-0060","volume-title":"Vaccine delivery:Bill and Melinda Gates Foundation"},{"key":"2022021406251049000_cei13284-bib-0061","author":"UK Vaccine network"},{"key":"2022021406251049000_cei13284-bib-0062","author":"Innovate UK-UK vaccine network"},{"key":"2022021406251049000_cei13284-bib-0063","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1016\/j.vaccine.2018.06.039","article-title":"Dual route vaccination for plague with emergency use applications","volume":"36","author":"Moore","year":"2018","journal-title":"Vaccine"},{"key":"2022021406251049000_cei13284-bib-0064","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1080\/21645515.2016.1175261","article-title":"Immunogenicity and safety of subunit plague vaccine: a randomized phase 2a clinical trial","volume":"12","author":"Chu","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"2022021406251049000_cei13284-bib-0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.vaccine.2018.11.022","article-title":"Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine","volume":"37","author":"Demeure","year":"2019","journal-title":"Vaccine"},{"key":"2022021406251049000_cei13284-bib-0066","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley Fever MP-12 vaccine Phase 2 clinical trial: safety, immunogenicity and genetic characterisation of virus isolates","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"2022021406251049000_cei13284-bib-0067","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.1016\/j.vaccine.2017.05.031","article-title":"Development of vaccines against CCHF virus","volume":"35","author":"Dowall","year":"2017","journal-title":"Vaccine"},{"key":"2022021406251049000_cei13284-bib-0068","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"key":"2022021406251049000_cei13284-bib-0069","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"2022021406251049000_cei13284-bib-0070","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralising antibodies elicited by recombinant Lassa\u2013Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Mota","year":"2018","journal-title":"Nat Commun"},{"key":"2022021406251049000_cei13284-bib-0071","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","article-title":"ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice","volume":"35","author":"Alharbi","year":"2017","journal-title":"Vaccine"},{"key":"2022021406251049000_cei13284-bib-0072","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00104-16","article-title":"Vaccine and therapeutic options to control chikungunya virus","author":"Powers","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2022021406251049000_cei13284-bib-0073","author":"Chikungunya vaccines in the pipeline"},{"key":"2022021406251049000_cei13284-bib-0074","doi-asserted-by":"crossref","first-page":"e01926","DOI":"10.1128\/mBio.01926-18","article-title":"A bacteriophage T4 nanoparticle based dual vaccine against anthrax and plague","volume":"9","author":"Tao","year":"2018","journal-title":"MBio"},{"key":"2022021406251049000_cei13284-bib-0075","volume-title":"WHO: Health products in the pipeline for infectious diseases"},{"key":"2022021406251049000_cei13284-bib-0076","volume-title":"WHO vaccine pipeline tracker","author":"World Health Organization"},{"key":"2022021406251049000_cei13284-bib-0077","author":"FDA guidances for vaccine development"},{"key":"2022021406251049000_cei13284-bib-0078","author":"EMA guideline for vaccine development"},{"key":"2022021406251049000_cei13284-bib-0079","author":"WHO guidance for clinical evaluation of vaccines"},{"key":"2022021406251049000_cei13284-bib-0080","author":"WHO vaccine standards: vaccine prequalification"},{"key":"2022021406251049000_cei13284-bib-0081","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/bsp.2007.0064","article-title":"The anthrax vaccine and research: reactions from postal workers and public health professionals","volume":"6","author":"Quinn","year":"2008","journal-title":"Biosecur Bioterror"},{"key":"2022021406251049000_cei13284-bib-0082","first-page":"37988","article-title":"Evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible","volume":"67","author":"21CFR 601.90-95","year":"2002","journal-title":"Fed Regist"},{"key":"2022021406251049000_cei13284-bib-0083","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1586\/erv.10.22","article-title":"Predictive models and correlates of protection for testing biodefence vaccines","volume":"9","author":"Williamson","year":"2010","journal-title":"Exp Rev Vaccines"},{"key":"2022021406251049000_cei13284-bib-0084","doi-asserted-by":"crossref","first-page":"16013","DOI":"10.1038\/npjvaccines.2016.13","article-title":"First vaccine approval under the FDA Animal rule","volume":"1","author":"Beasley","year":"2016","journal-title":"Npj Vaccines"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13284","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/198\/2\/170\/42507421\/cei13284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/198\/2\/170\/42507421\/cei13284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T06:30:26Z","timestamp":1644820226000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/198\/2\/170\/6402655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":84,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,4,11]]},"published-print":{"date-parts":[[2019,10,17]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13284","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,4,11]]}}}